Deletion of the FHL2 gene attenuating neovascularization after corneal injury.
暂无分享,去创建一个
Ju Chen | Shih-Ming Jung | P. Chu | I. Wang | L. Yeh | D. H. Ma | Hsin-Chiung Lin | Hsueh-Hua Wu | Tzu-Fang Shiu
[1] Jian-xing Ma,et al. Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy , 2007, Progress in Retinal and Eye Research.
[2] Ear Infirmary. CORNEAL ANGIOGENIC PRIVILEGE: ANGIOGENIC AND ANTIANGIOGENIC FACTORS IN CORNEAL AVASCULARITY, VASCULOGENESIS, AND WOUND HEALING (AN AMERICAN OPHTHALMOLOGICAL , 2006 .
[3] U. Moens,et al. The multifunctional roles of the four-and-a-half-LIM only protein FHL2 , 2006, Cellular and Molecular Life Sciences CMLS.
[4] T. Tsukada,et al. FHL5, a novel actin-binding protein, is highly expressed in eel gill pillar cells and responds to wall tension. , 2004, American journal of physiology. Regulatory, integrative and comparative physiology.
[5] M. Beckerle,et al. The LIM domain: from the cytoskeleton to the nucleus , 2004, Nature Reviews Molecular Cell Biology.
[6] R. Schüle,et al. The LIM-only Proteins FHL2 and FHL3 Interact with α- and β-Subunits of the Muscle α7β1 Integrin Receptor* , 2004, Journal of Biological Chemistry.
[7] R. Schüle,et al. Extracellular Signal-Regulated Kinase 2 Interacts with and Is Negatively Regulated by the LIM-Only Protein FHL2 in Cardiomyocytes , 2004, Molecular and Cellular Biology.
[8] R. Schüle,et al. The LIM-only proteins FHL2 and FHL3 interact with alpha- and beta-subunits of the muscle alpha7beta1 integrin receptor. , 2004, The Journal of biological chemistry.
[9] Jonathan T. Lu,et al. Gene-engineered models for genetic manipulation and functional analysis of the cardiovascular system in mice. , 2003, Chang Gung medical journal.
[10] Sung-Chul Lim,et al. Correlation of cyclooxygenase-2 pathway and VEGF expression in head and neck squamous cell carcinoma. , 2003, Oncology reports.
[11] J. Ambati,et al. Inhibition of Corneal Neovascularization by Genetic Ablation of CCR2 , 2003, Cornea.
[12] R. Gilbert,et al. COX-2 inhibition and retinal angiogenesis in a mouse model of retinopathy of prematurity. , 2003, Investigative ophthalmology & visual science.
[13] M. Buendia,et al. Identification of the LIM Protein FHL2 as a Coactivator of β-Catenin* , 2003, The Journal of Biological Chemistry.
[14] J. Ambati,et al. Sustained inhibition of corneal neovascularization by genetic ablation of CCR5. , 2003, Investigative ophthalmology & visual science.
[15] M. Buendia,et al. Identification of the LIM protein FHL2 as a coactivator of beta-catenin. , 2003, The Journal of biological chemistry.
[16] M. Kühl,et al. The LIM-only protein FHL2 interacts with β-catenin and promotes differentiation of mouse myoblasts , 2002, The Journal of cell biology.
[17] J. Ambati,et al. Angiostatin inhibits and regresses corneal neovascularization. , 2002, Archives of ophthalmology.
[18] S. Fan,et al. Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. , 2001, American journal of clinical pathology.
[19] Y. Sugisaki,et al. Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. , 2001, The American journal of pathology.
[20] P. Sassone-Corsi,et al. Transcriptional cascades during spermatogenesis: pivotal role of CREM and ACT , 2001, Molecular and Cellular Endocrinology.
[21] R. Bassel-Duby,et al. Cardiac-Specific LIM Protein FHL2 Modifies the Hypertrophic Response to &bgr;-Adrenergic Stimulation , 2001, Circulation.
[22] M. Sunday,et al. Differential expression of VEGF isoforms in mouse during development and in the adult , 2001, Developmental dynamics : an official publication of the American Association of Anatomists.
[23] D. Azar,et al. Corneal neovascularization. , 2001, Current opinion in ophthalmology.
[24] L. Liotta,et al. Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[25] A. Ghosh,et al. Cyclooxygenase-2-mediated angiogenesis in carrageenin-induced granulation tissue in rats. , 2000, The Journal of pharmacology and experimental therapeutics.
[26] J. Ross,et al. FHL2 (SLIM3) Is Not Essential for Cardiac Development and Function , 2000, Molecular and Cellular Biology.
[27] L. Aiello,et al. Role of vascular endothelial growth factor in diabetic vascular complications. , 2000, Kidney international. Supplement.
[28] C. Humpel,et al. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. , 2000, Investigative ophthalmology & visual science.
[29] Qiang Zhou,et al. Expression patterns of FHL/SLIM family members suggest important functional roles in skeletal muscle and cardiovascular system , 2000, Mechanisms of Development.
[30] S. Yamashina,et al. Cyclo‐oxygenase‐2 enhances basic fibroblast growth factor‐induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants , 2000, British journal of pharmacology.
[31] S. Dey,et al. Host cyclooxygenase-2 modulates carcinoma growth. , 2000, The Journal of clinical investigation.
[32] K. Seibert,et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. , 2000, Cancer research.
[33] R. DuBois,et al. Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells , 1998, Cell.
[34] R. Harvey,et al. An HF-1a/HF-1b/MEF-2 combinatorial element confers cardiac ventricular specificity and established an anterior-posterior gradient of expression. , 1996, Development.
[35] H. Dvorak,et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.
[36] J. Folkman. Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.